Delphi Management Partners Viii, L.L.C is an investment fund managing more than $127 million ran by Matthew Potter. There are currently 4 companies in Mr. Potter’s portfolio. The largest investments include Tandem Diabetes, Inc. and Karyopharm Therapeutics Inc, together worth $121 million.
As of 5th August 2021, Delphi Management Partners Viii, L.L.C’s top holding is 1,000,000 shares of Tandem Diabetes, Inc. currently worth over $97.4 million and making up 76.9% of the portfolio value.
In addition, the fund holds 2,263,006 shares of Karyopharm Therapeutics Inc worth $23.4 million, whose value fell 65.6% in the past six months.
The third-largest holding is Calithera Biosciences Inc worth $5.07 million and the next is Mereo BioPharma plc worth $814 thousand, with 256,734 shares owned.
Currently, Delphi Management Partners Viii, L.L.C's portfolio is worth at least $127 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Delphi Management Partners Viii, L.L.C office and employees reside in San Mateo, California. According to the last 13-F report filed with the SEC, Matthew Potter serves as the Chief Financial Officer at Delphi Management Partners Viii, L.L.C.
There are companies that Delphi Management Partners Viii, L.L.C is getting rid of from its portfolio.
Delphi Management Partners Viii, L.L.C closed its position in Senseonics Inc on 12th August 2021.
It sold the previously owned 9,846,294 shares for $8.59 million.
The two most similar investment funds to Delphi Management Partners Viii, L.L.C are Legg Mason, Inc and Intrack Investment Management Inc. They manage $127 million and $127 million respectively.
Delphi Management Partners Viii, L.L.C’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 23.1% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $263 million.
These positions were updated on August 12th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Tandem Diabetes, Inc. |
No change
1,000,000
|
$97,400,000 | 76.91% |
| Karyopharm Therapeutics Inc |
No change
2,263,006
|
$23,354,000 | 18.44% |
| Senseonics Holdings Inc |
Closed
9,846,294
|
$8,585,000 | |
| Calithera Biosciences Inc |
No change
2,426,702
|
$5,072,000 | 4.01% |
| Mereo BioPharma Group plc |
No change
256,734
|
$814,000 | 0.64% |
| No transactions found | |||
| Showing first 500 out of 5 holdings | |||